Skip to main content
Premium Trial:

Request an Annual Quote

Cisbio Inks Technology Licensing Deals, Collaborations for HTRF Technology

NEW YORK, Aug. 9 (GenomeWeb News) - Cisbio International said today that it has signed deals under which its homogenous time-resolved fluorescence technology will be incorporated into the measurement instrumentation systems used by BMG Labtech, Tecan, and Molecular Devices for drug discovery.


Under the terms of the agreements, each company will license Cisbio's HTRF technology for use in their high-performance time-resolved fluorescence microplate readers that are used in HTRF-based assays.


Cisbio also announced today that it has signed collaborations with Cell Signaling Technology and Upstate to expand use of the HTRF technology.


According to Cisbio, Cell Signaling has agreed to supply a select group of native antibodies and substrates that Cisbio will label and market for use in conjunction with HTRF. Separately, Upstate has agreed to use the HTRF technology with its assay for PI-3 kinase.


Additional terms of all five deals were not disclosed.


The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.